Loading stock data…
CGEN
$2.71+0.05 (+1.88%)
Market ClosedLast close May 1
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Compugen Ltd. in the Healthcare sector is trading at $2.71. The stock is currently 16% below its 52-week high of $3.24, remaining 50.6% above its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why CGEN maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.71
Potential Upside
234.1%
Whystock Fair Value$9.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consist...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$268.77M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
7.45
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
34.40%
Volume
Today's trading volume
426,383
Recent News
Compugen Highlights AI-Driven IO Pipeline, Key Trial Timelines and Big Pharma Partnerships at Needham Conference
Compugen (NASDAQ:CGEN) outlined progress across its immuno-oncology pipeline and partnerships at the Needham & Company Healthcare Conference, emphasizing the company’s AI-driven target discovery platform and multiple programs now in or approaching clinical readouts. Gil Blum, a senior analyst a
Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year
Compugen Ltd. (NASDAQ:CGEN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-quarter revenue of $67.3 million compared with $1.5 million in the prior year. Chief Executive Officer Eran Ophir said the company made important progress in 2025, citing the extension of its cash […]
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Compugen Ltd (CGEN) reports significant revenue increase and extends cash runway into 2029, despite challenges in trial timelines.
Compugen Ltd. Q4 2025 Earnings Call Summary
Moby summary of Compugen Ltd.'s Q4 2025 earnings call
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of +1,053.85% and +276.79%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?